Publications found:
259,187
Sort by:
Eisai - Catalysts Too Weak to Mitigate Key Patent Expiries
US$ 140.00
... Nov-10 and May-13 respectively); together they contributed ~56% of revenue in FY 03/11. Eisai solely depends on catalysts coming out of its pipeline. Following Halaven approval ... , Eisai has three late stage candidates E-2007/ perampanel ...
August 2011
8 pages
Roche, BMY - Zelboraf (Vemurafenib) approval- Competition to YERVOY starts
US$ 90.00
The USFDA approval of Zelboraf (Vemurafenib) for inoperable metastatic melanoma, well in advance of the PDUFA date is encouraging. USFDA has also approved the cobas BRAF mutation diagnostic test. This will reduce YERVOY uptake directly as ~50% of Metastatic Melanoma patients are B-RAF positive and Zelboraf ...
August 2011
2 pages
Gilead - Complera Approval - Positive Long Term Impact
US$ 90.00
Approval of Complera (GILD’s Truvada + Tibotec’s Edurant) reiterates GILD’s ... HIV infection. With the current economic turmoil, approval of once-daily Complera (formerly Fixed Dose Combination drug) impact may ... report released on 12th August, 2011, titled – “Complera Approval - Positive Long Term Impact”
August 2011
5 pages
Ranbaxy - When Will The Base Business Stabilize?
US$ 140.00
We reiterate our Market Perform rating on Ranbaxy after the Q2 CY11 result that was in line with our ... about a possible timely launch. Longer term potential of Ranbaxy seems promising with Daiichi-Ranbaxy likely to become the largest generic company in Japan ...
August 2011
6 pages
Cipla - Margin Improvement - A Healthy Sign.
US$ 140.00
... higher than our earnings estimate owing to the sharp improvement in gross margin. The improvement in gross margin (up by 330 bps, Y-o-Y) is largely due to the ... day exclusivity and (2) improvement in margin as contribution from Indore facility increases. For the longer term, CIPLA’s traditional business model ...
August 2011
6 pages
Celgene - Global Share Gains Continue + Pipeline Potential
US$ 140.00
... all commercial metrics – global share and duration gains, continued expansion of market ... access through approvals and reimbursements in the US and international market, and noteworthy operating efficiency places Celgene ... – “Global Share Gains Continue + Pipeline Potential”.
August 2011
6 pages
IPCA- Margin Improvement, Despite Lower Domestic Sales
US$ 140.00
... sales in WHO member countries. We expect several growth drivers for Ipca in the near term. (1) US generics growth even without the ... WHO member countries and branded formulations (3) margin improvement as sales mix improves in favor of formulation sales. We see Ipca as the best bet in the domestic formulations ...
August 2011
5 pages
TAKEDA - Multiple Challenges Blur Future!
US$ 140.00
There are three major concerns for Takeda – 1) Takeda has got European exposure by the Nycomed acquisition, but as both ... is expected. 2) Safety related issues with Actos affects market prospects of Takeda’s key candidate Aloglipin’s combination drug with Actos and, 3) Pipeline ...
August 2011
8 pages
Sun Pharma- Strong Margin Indicates A Strong Product Portfolio
US$ 140.00
Sun Pharma’s Q1 FY12 result was largely in line with our ... performance was not quite upto the mark, however, EBITDA margin improved by 300 bps Q-o-Q (Y-o-Y not relevant owing to launch of ... peers in the pharma space due to its rich, highly probable and yet hidden Para IV pipeline, strong balance sheet, likely ...
August 2011
8 pages
China Freeze Drying System Industry Report, 2011 - 2012
US$ 1,600.00
With the rapid development of pharmaceutical industry in China, the market size of freeze drying equipment continuously expands, which reached RMB2.425 billion in 2009, including the market of cleanin...
July 2011
53 pages
U.S. Market for Surgical Gowns
US$ 3,995.00
... and patient from operative and post-operative infection. In the 1960s, surgical gowns became more specialized, incorporating an exhaust helmet system, which ... two companies in the United States—Stryker and Ecolab—provided such highly protective gowns and helmet systems to the U.S. market. Scope: This report ...
July 2011
56 pages
Dishman - Moving away from CRAMS
US$ 140.00
Dishman’s Q1 FY12 result was below our expectations ... Amcis. The standalone EBITDA increased largely driven by sales from disinfectants in India, supply of intermediate of Brilinta to Astra Zeneca and ... most of them (except for Brilinta intermediate supply) coming from its non-CRAM business. On CRAMs part, we see ...
July 2011
5 pages
Lupin - Impact of Thin Pipeline Showing Up
US$ 140.00
... reiterate our Underperform with target price of `360 on Lupin after its Q1FY12 result that reflected a reduction in ... fag end of the quarter impacted the overall performance. We have always remained concerned about Lupin’s thin US pipeline along with a ... higher depreciation to eat into the earnings of Lupin.
July 2011
8 pages
Global Protein Therapeutics Market Analysis
US$ 1,800.00
Single User PDF Format: US$ 1,800.00
Multi-User License: US$ 2,800.00
Hard Copy: US$ 2,200.00
CD-ROM: US$ 2,200.00 Within the global pharmaceutical industry, protein therapeutics has b...
July 2011
180 pages
China Diabetes Market Analysis
US$ 800.00
Single User PDF Format: US$ 800.00
Multi-User License: US$ 1,200.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00 Diabetes has emerged as one of the most common diseases in China, affecting...
July 2011
50 pages
Global Biosimilars Market Analysis
US$ 1,400.00
Single User PDF Format: US$ 1,400.00
Multi-User License: US$ 1,800.00
Hard Copy: US$ 1,500.00
CD-ROM: US$ 1,500.00 The global biosimilars industry has been growing stupendously since t...
July 2011
65 pages
US e-health Market Analysis
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,500.00
Hard Copy: US$ 1,100.00
CD-ROM: US$ 1,100.00 The US represents one of the most developed healthcare markets global...
July 2011
75 pages
Market Access Brazil: Unlocking Pharma Potential
US$ 795.00
With this year’s election of president Dilma Rousseff, Brazil has indicated a willingness to encourage long-term foreign investment in the pharmaceutical industry. Yet while Rousseff has set three cri...
July 2011
38 pages
The Impact of iPads on pharma: a Primer
US$ 245.00
With the launch of Apple's iPad in April 2010, the way we use technology changed forever. Instant, portable and quick, the iPad is expected to sell 50 million units in 2011 alone.
Its impact...
July 2011
33 pages
China Monoclonal Antibody Industry Report, 2010-2011
US$ 1,700.00
China has been engaging in the R&D of monoclonal antibody industry for a long time, but still lags far behind the European and American countries in terms of industrialization. In 2010, the market...
July 2011
64 pages
U.S. Market for Women's Health Devices 2011
US$ 7,495.00
... based Fluid management: capital equipment and tubing Within the Women’s Health market, companies such as Boston Scientific, Conceptus, Fujifilm Medical Systems ... , Hologic, Johnson & Johnson and Philips Medical Systems lead the market, among many others. This report provides a comprehensive and detailed ...
July 2011
413 pages
Latin American Markets for Spinal Implants and VCF 2011
US$ 7,495.00
The Latin American Market includes the following countries: Argentina, Brazil, and Mexico In 2010, the Latin American market for spinal implants, consisting of: cervical fixation, thoracolumbar fixation, interbody fusion, dynamic stabilization, artificial discs, VCF, MIS interbody fusion ...
July 2011
558 pages
U.S. Hyaluronic Acid Viscosupplementation Physician Survey 2011
US$ 7,495.00
Over 100 orthopedic specialists were surveyed regarding their perceptions and usage of hyaluronic acid viscosupplementation during the 2011 American Academy of Orthopaedic Surgeons (AAOS) conference. This survey report compares usage patters and perceptions of orthopedic specialists regarding hyaluronic acid ...
July 2011
80 pages
International Hyaluronic Acid Viscosupplementation Physician Survey 2011
US$ 11,495.00
Over 100 orthopedic specialists were surveyed regarding their perceptions and usage of hyaluronic acid viscosupplementation during the 2011 American Academy of Orthopaedic Surgeons (AAOS) conference. This survey report compares usage patters and perceptions of orthopedic specialists regarding hyaluronic acid ...
July 2011
91 pages
Generic Drugs in Consumer Health Global Overview 2011
US$ 2,000.00
... are slowly becoming an ally in a strategy to boost sales. Euromonitor International’s Generic Drugs in Consumer Health Global Overview 2011 global briefing examines the ... data. Why buy this report? Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors driving ...
July 2011
50 pages
Global Cord Blood Banking Market: Focus on China
US$ 700.00
... about cord blood banking. Key issues like entry barriers in cord blood banking, collection and storage problem have been discussed. The competition prevailing in the global cord blood banking market has ...
July 2011
35 pages
Competitor Analysis: Heat shock protein 90 (Hsp90) Inhibitors
US$ 275.00
... The present Competitive Intelligence report about Heat shock protein 90 (Hsp90) Inhibitors provides a competitor evaluation in the field of novel small molecules ... database will be sent by e-mail and allow online work with the project data to print or export an individual report. Inhibition of heat shock ...
July 2011
26 pages
Global Top 10 Medical Devices Market (2010 - 2015)
US$ 5,650.00
The study of global top 10 medical devices market is important mainly due to continuous technological advancements in the medical devices industry and rising demand for medical devices owing to increasing healthcare issues. This report not only provides a full estimate of the global top 10 medical device ...
July 2011
575 pages
Competitor Analysis: HDAC Inhibitors
US$ 550.00
... the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Histone deacetylase (HDAC) ... class I and II Inhibitors Multi-Target HDAC Inhibitors Others Corporate HDAC Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The ...
July 2011
58 pages
Regeneron - Entering the Commercial TRAP
US$ 140.00
... US next month (PDUFA: August, 20). What are the risks to its commercial success and future of REGN’s pipeline? A comprehensive analysis about the ...
July 2011
7 pages
CADILA HEALTHCARE LTD - In a Consolidation Phase
US$ 140.00
CDH’s Q1 FY12 adjusted result (adjusted to the milestone income from Abbott) was below our sales and earnings estimate. Higher base created in FY11 by pushing product sales last year to achieve the $1b sales mark was the main reason for a muted performance in most of the business divisions. While the ...
July 2011
6 pages
Novartis vs. Peer group- Growth rate differential to widen going forward
US$ 90.00
Novartis reported solid revenue growth driven by Sandoz, recently launched products and Alcon Acquisition. Going ... shape up in the longer term. Novartis is in better position to return back profits to investors compare to its global peers in unfavorable environment mainly due to its ...
July 2011
2 pages
